Key result
Type 2 cardiorenal syndrome is linked to ~4-fold higher in-hospital mortality in heart failure.
Why the study?
Chronic heart failure and subsequent secondary renal impairment, classified as type 2 cardiorenal syndrome, are becoming increasingly prevalent, aggravate morbidity and mortality, and limit many therapeutic options.
Answers are grounded in this paper and cite their sources.
Alerts clinicians to screen for secondary renal impairment in chronic HF; leaves open optimal diagnostic criteria and interventions.
The most important advancements in the Cardiorenal syndrome (CRS) are its definition and subsequent classifications. When the predominant pathology and pathophysiology is the heart, i.e. chronic heart failure (CHF), and where any renal impairment (RI) subsequent to this is secondary, the classification is type 2 CRS. There are unique differences in the pathophysiology and progression of individual subclasses. It is important to understand the evolution of CHF and consequences of subsequent RI as they are becoming increasingly prevalent, aggravate morbidity and mortality and limit many therapeutic options. In this paper we discuss the significance of the type 2 CRS patients in the context of the thematic series.
No takes yet. Share an insight, caveat, or question.
Jois et al. (2016) conducted a review in Type 2 Cardiorenal Syndrome (Chronic Heart Failure with Comorbid Renal Dysfunction). Type 2 cardiorenal syndrome is characterized by chronic heart failure causing secondary renal impairment, which is frequently underdiagnosed and undertreated while increasing in-hospital mortality from 1.9% to 7.6%.
Synapse has enriched 10 related papers. Consider them for comparative context: